Why the study?
Does disopyramide reduce ventricular premature depolarization in patients with frequent VPD?
Does disopyramide reduce ventricular premature depolarization in patients with frequent VPD?
Acute oral disopyramide effectively suppresses frequent ventricular premature depolarizations but is associated with anticholinergic side effects and potential aggravation of heart failure.
May support acute VPD suppression testing; leaves open durability, safety, and role versus modern therapies.
Acute antiarrhythmic drug testing with disopyramide was accomplished in 25 patients with frequent ventricular premature depolarization (VPD). Systolic time intervals (STI) were used to assess left ventricular performance. Eighteen patients responded after a loading oral dose of 300 mg disopyramide with 80% or greater reduction in VPD and abolition of advanced grades. Mean onset of drug action was 93 min and the mean plasma level at 2 h was 3.4 microgram /ml. During maintenance therapy 2 of the 18 patients had a relapse, In 2 others, initially protected, VPD recurred during both exercise and psychological stress testing. STI showed increments in pre-ejection period (PEP) and in PEP/ejection time ratio at peak concentrations of plasma disopyramide. Acute tests repeated with placebo in a single-blind fashion in responding patients failed to significantly reduce VPD frequency or grade. Side effects consisted of anticholinergic actions of disopyramide. In 3 patients aggravation of heart failure compelled discontinuation of disopyramide which then remitted.
No takes yet. Share an insight, caveat, or question.
García-Barreto et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: